• Home
  • The MMS Difference
    • About Us
    • Leadership
    • Certifications
  • Services
    • Regulatory Affairs and Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Drug Safety and Pharmacovigilance
    • Compliance and Transparency
    • Data Sciences
  • Working with MMS
  • News and Media
  • MMS Blog
  • Careers
  • Contact Us
MMS
Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope

Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope

by curtis@digitalliance.com | Jun 27, 2017 | Blog

Alzheimer’s Awareness and the Future of Clinical Development: Face the Scope and Don’t Lose Hope by Ben Kaspar, July 27, 2017 In the United States, the number of patients with Alzheimer’s disease is projected to increase from the current prevalence of around 5.5...

Recent Posts

  • Planning for Health Canada’s New Transparency Initiatives for Clinical Data
  • MMS HOLDINGS NAMED HONORABLE MENTION IN PRESTIGIOUS PR DAILY CORPORATE SOCIAL RESPONSIBILITY AWARDS FOR #ONEMMS VOLUNTEER INITIATIVE
  • Pharmaceutical Industry Experts Speak Out: Five Productivity Tips for Working from Home
  • Pharmaceutical Industry News Roundup: August 2019
  • Using Real World Data in Drug Development: Five Questions with Vijay Ivaturi, PhD

Tags

ALZ awareness Alzheimers big data biosimilars biostatistics Clinical Development clinical research clinical study reports clinical trials clinical trial transparency Community Compliance CRO data management data privacy data science drug development EMA ENDALZ FDA Flint GDPR GXP auditing Health Analytics Collective Health Canada Lay summaries leadership medical writing NDA submission News opioids pharma pharmacovigilance PhUSE Policy 0070 quality control real world data regulatory operations REMS resourcing statistical programming suicidality transparency trial regulation Volunteering